UBS Group »

Aeglea Biotherapeutics shares owned by UBS Group

Quarter-by-quarter ownership of Aeglea Biotherapeutics (SYRE) shares owned by UBS Group from 13F filings

Historical chart of UBS Group investment in Aeglea Biotherapeutics

Tip: Access up to 7 years of quarterly data

All positions including Aeglea Biotherapeutics held by UBS Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Aeglea Biotherapeutics by UBS Group

Quarter filed Position value Share count Share price at filing
2023-12-31 $80k 3.7k 21.52

More positions owned by UBS Group

Microsoft Corporation (MSFT)
Apple Call Option (AAPL)
Spdr S&p 500 Etf Tr Tr Unit (SPY)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Ishares Tr Russell 2000 Etf (IWM)
Amazon Call Option (AMZN)
NVIDIA Corporation (NVDA)
Ubs Group SHS (UBS)
Broadcom (AVGO)
JPMorgan Chase & Co. (JPM)
Alphabet Cap Stk Cl A (GOOGL)
Ishares Tr 20 Yr Tr Bd Etf (TLT)
Union Pacific Corporation (UNP)
Alphabet Cap Stk Cl C Put Option (GOOG)
Meta Platforms Cl A (META)

View all positions for UBS Group

Top funds holding Aeglea Biotherapeutics

Perceptive Advisors
VR Adviser
Commodore Capital
venBio Select Advisor
Cormorant Asset Management
EcoR1 Capital
Franklin Resources
BVF
Wellington Management Company
Citadel Advisors
Braidwell
Global Endowment Management
First Turn Management
Fairmount Funds Management
Boxer Capital

View all funds holding Aeglea Biotherapeutics